Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Olumiant for Rheumatoid Arthritis

Eli Lilly, Incyte news release; 2018 Jun 1

Eli Lilly and Company and Incyte Corporation have announced that the US Food and Drug Administration (FDA) has approved the 2-mg dose of Olumiant (baricitinib)—a once-daily, oral, Janus kinase (JAK) inhibitor—for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to ≥1 tumor necrosis factor (TNF) inhibitor therapies. Olumiant may be used as monotherapy or in combination with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs DMARDs. However, use of Olumiant in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

Eli Lilly and Company is headquartered in Indianapolis, IN; Incyte Corporation is based in Wilmington, DE.

Adverse reactions: Adverse reactions (≥1%) include upper respiratory tract infections, nausea, herpes simplex, and herpes zoster.

Citation:

FDA approves Olumiant (baricitinib) 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis. [news release]. Indianapolis, IN: Eli Lilly and Company, and Wilmington, DE: Incyte Corporation. June 1, 2018. https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults. Accessed July 3, 2018.

This Week's Must Reads

Long-term Opioid Use with Severe OA by Geography, Arthritis Rheumatol; ePub 2019 Jan 28; Desai, et al

Family History of Psoriasis and Psoriatic Disease, Arthritis Care Res; ePub 2019 Jan 25; Solmaz, et al

Remission/Low Disease Activity Protective in SLE , Lupus; ePub 2019 Jan 24; Alarcón, Ugarte-Gil, et al

Dietary Niacin Linked with Incident Hip Fracture, J Bone Miner Res; ePub 2019 Jan 19; Carbone, et al

Must Reads in FDA Actions

FDA Approves Hyrimoz for Chronic Conditions, Sandoz news release; 2018 Oct 31

FDA Approves Subcutaneous Actemra for Active SJIA, PharmaLive news release; 2018 Sep 13

FDA Approves Olumiant for Rheumatoid Arthritis, Eli Lilly, Incyte news release; 2018 Jun 1

FDA Approves Consensi for Osteoarthritis Pain, FirstWord Pharma news release; 2018 May 31

FDA Approves Prolia for GIOP in Men and Women, FirstWord Pharma news release; 2018 May 21